

To: 5.1.2e @mvpep.hr; 5.1.2e @mvpep.hr]; 5.1.2e @mfa.gov.lv; 5.1.2e @mfa.gov.lv];
 5.1.2e @bmeia.gv.at; 5.1.2e @bmeia.gv.at]; 5.1.2e @diplobel.fed.be; 5.1.2e @diplobel.fed.be]; 5.1.2e @bg-
 permrep.eu; 5.1.2e @bg-permrep.eu]; 5.1.2e @moh.gov.cy; 5.1.2e @moh.gov.cy];
 5.1.2e @mzv.cz; 5.1.2e @mzv.cz]; 5.1.2e @brue.auswaertiges-amt.de; 5.1.2e @brue.auswaertiges-amt.de];
 5.1.2e @diplo.de; 5.1.2e @diplo.de]; 5.1.2e @diplo.de; 5.1.2e @diplo.de];
 5.1.2e @um.dk; 5.1.2e @um.dk]; 5.1.2e @mfa.ee; 5.1.2e @mfa.ee];
 5.1.2e @reper.maec.es; 5.1.2e @reper.maec.es]; 5.1.2e @formin.fi; 5.1.2e @formin.fi];
 5.1.2e @diplomatie.gouv.fr; 5.1.2e @diplomatie.gouv.fr];
 5.1.2e @mfa.gov.hu; 5.1.2e @mfa.gov.hu]; 5.1.2e @dfa.ie; 5.1.2e @dfa.ie];
 5.1.2e @eu.mfa.lt; 5.1.2e @eu.mfa.lt]; 5.1.2e @mae.etat.lu; 5.1.2e @mae.etat.lu];
 5.1.2e @gov.mt; 5.1.2e @gov.mt]; 5.1.2e @minbuza.nl; 5.1.2e @minbuza.nl];
 5.1.2e @msz.gov.pl; 5.1.2e @msz.gov.pl]; 5.1.2e @reper-
 portugal.be; 5.1.2e @reper-portugal.be]; 5.1.2e @rpro.eu; 5.1.2e @rpro.eu]; 5.1.2e @gov.si; 5.1.2e @gov.si];
 5.1.2e @mzv.sk; 5.1.2e @mzv.sk]; 5.1.2e @gov.se; 5.1.2e @gov.se];
 5.1.2e @esteri.it; 5.1.2e @esteri.it]; 5.1.2e @gov.si; 5.1.2e @gov.si]; 5.1.2e @rp-
 grece.be; 5.1.2e @rp-grece.be]; 5.1.2e @diplomatie.gouv.fr; 5.1.2e @diplomatie.gouv.fr];
 5.1.2e @mfa.no; 5.1.2e @mfa.no];
 5.1.2e @bru.lv.li; 5.1.2e @bru.lv.li]; 5.1.2e @mfa.is; 5.1.2e @mfa.is];
Cc: 5.1.2e @ec.europa.eu; 5.1.2e @ec.europa.eu];
 5.1.2e @ec.europa.eu; 5.1.2e @ec.europa.eu];
From: 5.1.2e @ec.europa.eu
Sent: Fri 3/27/2020 1:27:55 PM
Subject: Follow-up videoconference 26 March - Request on MS needs with regards to the Indian export ban.
Received: Fri 3/27/2020 1:28:00 PM

Dear colleagues,

The European Commission is very keen to help Member States mitigate the risk of shortages of medicines linked to COVID-19. The EU Executive Steering Group on shortages of medicines caused by major events comprised of the European Commission, European Medicines Agency and the Heads of Medicines Agencies Network has been set up to provide strategic leadership for urgent and coordinated action within the EU in case a crisis caused by major events, such as the COVID-19 outbreak, risks impacting the supply of medicinal products for human and veterinary use.

We are aware of the current tensions in the supply of paracetamol, and to a lesser extent of ibuprofen. Industry has also warned of further shortages of these products due to increased stockpiling by citizens and surges in demand from hospitals. We are also concerned that Indian export ban may further exacerbate the situation. On 26 March, Commissioner Kyriakides had the opportunity to speak to the Indian Minister of Commerce and express concerns in relation to the risk of shortages of medicines linked to the Indian restrictions. She also explained the importance of maintaining supply for the benefit of patients around the world.

As requested by Commissioner Kyriakides in the videoconference on Thursday 26 March, we would like to ask Member States and EEA countries to communicate your needs for paracetamol, including which pharmaceutical forms are required, and your monthly forecasts taking into account the progression of the COVID-19 outbreak. Please also indicate if there are other shortages (monthly figures) that you anticipate in relation to Indian's export ban on specific active substances. It is important to have more information about the concrete needs of Member States before approaching the Indian authorities further. Commissioner Kyriakides has committed to facilitate a dialogue with India to mitigate any potential shortages due to Indian export ban.

Please send the information on needs of paracetamol and any other active substances affected by India's export ban to the European Medicines Agency (dedicated mailbox: 5.1.2e @ema.europa.eu) by **Monday 30 March at 15:00.**

Please note that this request was also already sent by the European Medicines Agency to your National Competent Authorities through the Single Point Of Contact (SPOC) system.

Kind regards,

5.1.2e